Inactive Instrument

Appliance Recycling Cntrs of Amer Inc Share Price Nasdaq

Equities

US03814F2056

Biotechnology & Medical Research

Sales 2022 39.61M 3.16B Sales 2023 - Capitalization 2.75M 219M
Net income 2022 11M 877M Net income 2023 -7M -558M EV / Sales 2022 0.41 x
Net Debt 2022 12.02M 958M Net Debt 2023 416K 33.16M EV / Sales 2023 -
P/E ratio 2022
0.39 x
P/E ratio 2023
-0.28 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 98.74%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 71 30/04/15
Director of Finance/CFO 64 20/08/17
Chief Tech/Sci/R&D Officer - 28/01/20
Members of the board TitleAgeSince
Chief Executive Officer 71 30/04/15
Director/Board Member 74 30/04/15
Director/Board Member 40 31/07/18
More insiders
JanOne Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying, acquiring, licensing, developing, partnering, and commercializing novel, no-opioid, and non-addictive therapies to address the large, unmet medical need for the treatment of pain and addiction. Its drug candidate, JAN101, is a patented oral, sustained-release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities, such as those with vascular complications of diabetes or Peripheral Artery Disease (PAD) and treats pain. The Company’s drug candidate is a treatment for Peripheral Artery Disease, a condition that can cause severe pain and affects over 8.5 million people in the United States. The Company operates through the Biotechnology segment, which is focused on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties.
More about the company